Fangzhou Inc. Recognized for AI Innovation in Healthcare, Secures Top Honors and National High-Tech Enterprise Status

Fangzhou Inc. Achieves Multiple Accolades for AI Innovation in Healthcare

Fangzhou Inc., a leading Chinese Internet healthcare solutions provider, has recently garnered significant recognition for its AI-driven innovations in the healthcare sector. The company has been honored with multiple awards and designations, highlighting its growing influence in the field of AI-powered healthcare technology.

Top Honors in Guangzhou's AI Innovation List

Fangzhou has been named to the 2024 Guangzhou Artificial Intelligence Innovation Development List as the "Most Promising Enterprise." Simultaneously, its H2H Smart Healthcare Ecosystem secured a spot on the "Application Scenario Innovation List" as one of the Top 10 AI+Healthcare Cases 3

3

. These awards, issued by the Guangzhou Municipal Science and Technology Bureau, underscore Fangzhou's contributions to transforming the digital healthcare industry.

National High-Tech Enterprise Certification

In a separate development, Beijing Fangyixing Information Technology Co., Ltd., a subsidiary of Fangzhou Inc., has been certified as a 2024 National High-Tech Enterprise. This prestigious designation, jointly awarded by Beijing's science, finance, and tax authorities, recognizes Fangyixing's strengths in core intellectual property, commercialization of scientific achievements, and robust R&D management 2

2

.

AI-Driven Healthcare Innovations

At the heart of Fangzhou's success is its H2H Smart Healthcare Ecosystem, which integrates advanced AI models and technologies:

1. The company has incorporated Tencent Health's DeepSeek-V3 and DeepSeek-R1 AI models into its upgraded AI Agent 2.0 platform 1

   1

   .

2. Four core AI modules power the H2H platform: AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant. These tools aim to streamline operations from diagnostics to supply chain management 3

   3

   .

3. Fangzhou leverages Tencent Cloud's infrastructure to enhance drug logistics and patient care efficiency 1

   1

   .

Impressive Market Reach and Financial Performance

Fangzhou's chronic disease management platform has demonstrated significant market penetration:

• The platform connects 49.2 million users and 223,000 physicians, offering personalized care and precision medicine services as of December 2024 1

  1

  .

• The company reported strong financial results, with 2024 revenue growing 11.2% year-over-year to RMB2.707 billion, and adjusted net profit increasing by 139% year-over-year to RMB17.1 million 2

  2

  .

Future Outlook and Strategic Vision

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, emphasized the company's commitment to scaling AI innovations within their H2H Smart Healthcare Ecosystem. The company plans to deepen collaborations with industry leaders and accelerate the translation of cutting-edge research into accessible healthcare solutions 2

2

.

As Fangzhou continues to invest in AI-enabled technologies, it aims to further strengthen its technological capabilities and accelerate the commercialization of innovations, with a focus on delivering improved user experiences for patients and customers in the rapidly evolving landscape of AI-driven healthcare.